{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:15:39Z","timestamp":1791778539651,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":4513,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1093\/annonc\/mdm178","type":"journal-article","created":{"date-parts":[[2007,8,11]],"date-time":"2007-08-11T11:12:39Z","timestamp":1186830759000},"page":"1369-1375","source":"Crossref","is-referenced-by-count":57,"title":["VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group"],"prefix":"10.1016","volume":"18","author":[{"given":"K","family":"Zervas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Mihou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Katodritou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Mitsouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Delibasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Kyrtsonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Zikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Maniatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm178_bb0010","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma, combination chemotherapy with different melphalan dose regimens","volume":"206","author":"Alexanian","year":"1969","journal-title":"J Am Med Assoc"},{"key":"10.1093\/annonc\/mdm178_bb0015","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan and prednisone as treatment of multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","author":"Myeloma Trialists' Collaborative Group","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm178_bb0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"336","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm178_bb0025","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","article-title":"Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdm178_bb0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdm178_bb0035","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(89)91549-3","article-title":"Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma","volume":"2","author":"Samson","year":"1989","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdm178_bb0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.1999.01279.x","article-title":"Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma","volume":"105","author":"Segeren","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdm178_bb0045","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10946","article-title":"A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed myeloma patients","volume":"95","author":"Hussein","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm178_bb0050","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","article-title":"Prospective randomized comparison of VAD administered as intravenous bolus injection and VAD with liposomal doxorubicin as first- line treatment in multiple myeloma","volume":"14","author":"Dimopoulos","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm178_bb0055","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Sinhgal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm178_bb0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2141.2003.03929.x","article-title":"Novel therapies for multiple myeloma","volume":"120","author":"Hayashi","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdm178_bb0065","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima T. Chauhan","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm178_bb0070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdh026","article-title":"Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study","volume":"15","author":"Zervas","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm178_bb0075","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haematopoietic stem cell transplantation","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdm178_bb0080","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdm178_bb0085","first-page":"155","article-title":"dexamethasone: a new standard of care for initial therapy in multiple myeloma","volume":"132","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm178_bb0090","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm178_bb0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm178_bb0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm178_bb0105","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2006-03-013086","article-title":"Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma","volume":"108","author":"Offidani","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm178_bb0110","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4065\/81.7.889","article-title":"Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma","volume":"81","author":"Hussein","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1093\/annonc\/mdm178_bb0115","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1182\/blood-2006-07-034538","article-title":"Complete response in myeloma: a Trojan horse?","volume":"108","author":"Barlogie","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm178_bb0120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1703818","article-title":"Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single center experience in 127 patients","volume":"31","author":"Terpos","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdm178_bb0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1704545","article-title":"High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdm178_bb0130","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","article-title":"Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring","volume":"24","author":"Mileshkin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm178_bb0135","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1200\/JCO.2003.07.200","article-title":"Treatment of plasma cell dyscrasias with thalidomide and its derivatives","volume":"21","author":"Dimopoulos","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm178_bb0140","first-page":"104","article-title":"Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma","author":"Baz","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm178_bb0145","first-page":"584","article-title":"Aspirin prophylaxis during treatment of multiple myeloma using liposomal doxorubicin, vincristine decreased-frequency dexamethasone & thalidomide decreases post-treatment thrombosis","volume":"22","author":"Tso","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm178_bb0150","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep venous thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoangulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdm178_bb0155","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdm178_bb0160","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdm178_bb0165","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"108","author":"Rajkumar","year":"2005","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419429062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419429062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/8\/1369\/19446672\/mdm178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T14:55:05Z","timestamp":1582210505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419429062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0923753419429062"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm178","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}